Oppenheimer's 25th Annual Healthcare Conference Provides Investors With Access To Public And Private Healthcare Companies

Dec 12, 2014, 09:00 ET from Oppenheimer & Co. Inc.

NEW YORK, Dec. 12, 2014 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings Inc., hosted its 25th Annual Healthcare Conference at The Crowne Plaza Hotel in New York City on December 10 – 11, 2014.

In attendance were more than 140 public and private companies across the healthcare industry, including bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers and servicers. The two-day conference, which featured company presentations and 1-on-1 meetings, attracted more than 750 healthcare executives, investors and companies across the spectrum.

"Oppenheimer is firmly committed to healthcare and this event has been a key conference for us over the past 25 years. We are pleased once again to offer the opportunity to host over 140 companies and to provide investors the ability to identify new products and trends within the entire healthcare sector," said Erica Moffett, Managing Director and Associate Director of Research.

Conferences are only open to established institutional clients of Oppenheimer & Co. Inc. For more information, please contact your Oppenheimer & Co. Inc. institutional sales representative.

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc.

(OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.

SOURCE Oppenheimer & Co. Inc.